CA2691736A1 - Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human - Google Patents

Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human Download PDF

Info

Publication number
CA2691736A1
CA2691736A1 CA002691736A CA2691736A CA2691736A1 CA 2691736 A1 CA2691736 A1 CA 2691736A1 CA 002691736 A CA002691736 A CA 002691736A CA 2691736 A CA2691736 A CA 2691736A CA 2691736 A1 CA2691736 A1 CA 2691736A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
lopinavir
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002691736A
Other languages
English (en)
French (fr)
Inventor
Brian P. Kearney
Anita A. Mathias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2691736A1 publication Critical patent/CA2691736A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002691736A 2007-06-29 2008-06-26 Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human Abandoned CA2691736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94732507P 2007-06-29 2007-06-29
US60/947,325 2007-06-29
PCT/US2008/068351 WO2009006203A1 (en) 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof

Publications (1)

Publication Number Publication Date
CA2691736A1 true CA2691736A1 (en) 2009-01-08

Family

ID=39817166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002691736A Abandoned CA2691736A1 (en) 2007-06-29 2008-06-26 Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human

Country Status (21)

Country Link
US (4) US20110009411A1 (enExample)
EP (1) EP2167089A1 (enExample)
JP (3) JP5547067B2 (enExample)
KR (1) KR20100028656A (enExample)
CN (2) CN101743004A (enExample)
AP (1) AP2490A (enExample)
AR (1) AR067184A1 (enExample)
AU (1) AU2008270634B2 (enExample)
BR (1) BRPI0813955A2 (enExample)
CA (1) CA2691736A1 (enExample)
CO (1) CO6251236A2 (enExample)
EA (1) EA200971096A1 (enExample)
EC (1) ECSP109889A (enExample)
IL (1) IL202745A0 (enExample)
MX (1) MX2009013828A (enExample)
NZ (1) NZ582089A (enExample)
SG (1) SG182228A1 (enExample)
TW (1) TW200916103A (enExample)
UA (1) UA103881C2 (enExample)
WO (1) WO2009006203A1 (enExample)
ZA (1) ZA201000468B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
PL2049506T5 (pl) 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
WO2008033836A2 (en) 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
MX2009008935A (es) * 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
EP2555757B1 (en) * 2010-04-09 2016-05-25 Bristol-Myers Squibb Holdings Ireland Atazanavir sulfate formulations with improved ph effect
US20130274254A1 (en) * 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
HK1204980A1 (en) * 2012-03-01 2015-12-11 Gilead Sciences, Inc. Spray dried formulations
AU2013296289B2 (en) 2012-08-03 2017-10-05 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
NO2865735T3 (enExample) 2013-07-12 2018-07-21
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
SK2662004A3 (sk) * 2002-11-20 2005-06-02 Japan Tobacco, Inc. Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz
WO2005034001A1 (en) * 2003-10-09 2005-04-14 Steven Wheeler Adaptive medical decision support system
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EP1758581A1 (en) * 2004-05-21 2007-03-07 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP1976517A1 (en) * 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
PL2049506T5 (pl) * 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
WO2008033836A2 (en) * 2006-09-12 2008-03-20 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010011963A (es) * 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
US20110000941A1 (en) * 2009-07-06 2011-01-06 Volk J Patrick Apparatus and System for Carrying a Digital Media Player

Also Published As

Publication number Publication date
ZA201000468B (en) 2011-06-29
EA200971096A1 (ru) 2010-08-30
US20170136000A1 (en) 2017-05-18
ECSP109889A (es) 2010-03-31
IL202745A0 (en) 2010-06-30
AP2009005083A0 (en) 2009-12-31
AR067184A1 (es) 2009-09-30
CN101743004A (zh) 2010-06-16
JP2010532373A (ja) 2010-10-07
AU2008270634A1 (en) 2009-01-08
US20090093482A1 (en) 2009-04-09
BRPI0813955A2 (pt) 2017-05-09
MX2009013828A (es) 2010-03-10
KR20100028656A (ko) 2010-03-12
WO2009006203A1 (en) 2009-01-08
JP2015143277A (ja) 2015-08-06
SG182228A1 (en) 2012-07-30
UA103881C2 (ru) 2013-12-10
JP2013199494A (ja) 2013-10-03
EP2167089A1 (en) 2010-03-31
TW200916103A (en) 2009-04-16
NZ582089A (en) 2013-01-25
US20110009411A1 (en) 2011-01-13
US20140343062A1 (en) 2014-11-20
AP2490A (en) 2012-10-04
CO6251236A2 (es) 2011-02-21
AU2008270634B2 (en) 2014-01-16
JP5769762B2 (ja) 2015-08-26
JP5547067B2 (ja) 2014-07-09
CN103356622A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
AU2008270634B2 (en) Therapeutic compositions and the use thereof
AU2008270630B2 (en) Therapeutic compositions and the use thereof
AU2006332664B2 (en) Methods for improving the pharmacokinetics of HIV integrase inhibitors
HK1156259A (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130403

FZDE Discontinued

Effective date: 20170710